Prestige Consumer Healthcare’s (PBH) Buy Rating Reiterated at DA Davidson

DA Davidson reaffirmed their buy rating on shares of Prestige Consumer Healthcare (NYSE:PBH) in a research note released on Monday,Benzinga reports. DA Davidson currently has a $95.00 price target on the stock. DA Davidson also issued estimates for Prestige Consumer Healthcare’s Q3 2025 earnings at $1.16 EPS and FY2025 earnings at $4.46 EPS.

Separately, Jefferies Financial Group reissued a “hold” rating and set a $76.00 price target (up previously from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of “Moderate Buy” and a consensus price target of $94.20.

Prestige Consumer Healthcare Price Performance

PBH stock opened at $82.81 on Monday. The stock has a 50-day moving average price of $72.98 and a two-hundred day moving average price of $70.09. Prestige Consumer Healthcare has a 1 year low of $56.61 and a 1 year high of $83.83. The stock has a market cap of $4.09 billion, a PE ratio of 20.15, a price-to-earnings-growth ratio of 2.32 and a beta of 0.47. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, November 7th. The company reported $1.09 EPS for the quarter, meeting the consensus estimate of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The firm had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. During the same period in the prior year, the firm posted $1.07 earnings per share. The business’s quarterly revenue was down .9% compared to the same quarter last year. Equities analysts forecast that Prestige Consumer Healthcare will post 4.45 EPS for the current fiscal year.

Insider Transactions at Prestige Consumer Healthcare

In related news, insider William P’pool sold 8,987 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total value of $735,585.95. Following the sale, the insider now owns 20,058 shares in the company, valued at $1,641,747.30. This represents a 30.94 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Mary Beth Fritz sold 9,885 shares of the company’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $81.97, for a total transaction of $810,273.45. Following the completion of the transaction, the senior vice president now owns 18,835 shares in the company, valued at approximately $1,543,904.95. The trade was a 34.42 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 27,935 shares of company stock valued at $2,289,025. Company insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in PBH. Ariel Investments LLC raised its holdings in Prestige Consumer Healthcare by 10.7% during the second quarter. Ariel Investments LLC now owns 2,835,203 shares of the company’s stock valued at $195,204,000 after acquiring an additional 274,212 shares during the period. Victory Capital Management Inc. grew its holdings in shares of Prestige Consumer Healthcare by 9.0% in the second quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock worth $142,827,000 after purchasing an additional 171,357 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Prestige Consumer Healthcare by 19.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,575,170 shares of the company’s stock valued at $113,570,000 after buying an additional 255,045 shares during the period. Congress Asset Management Co. raised its position in shares of Prestige Consumer Healthcare by 7.8% in the 3rd quarter. Congress Asset Management Co. now owns 865,123 shares of the company’s stock worth $62,375,000 after acquiring an additional 62,411 shares in the last quarter. Finally, Boston Trust Walden Corp purchased a new stake in Prestige Consumer Healthcare during the third quarter valued at approximately $41,785,000. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.